Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs

Focal Epilepsy Clinical Trial

— STEP-ONE  

Official title:

A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00438451
• Other study ID #: STEPONE05
• Secondary ID: ISRCTN: 94839639
• Status: Completed
• Phase: Phase 4
• First received: February 21, 2007
• Last updated: January 24, 2013
• Start date: January 2007
• Est. completion date: August 2011

Study information

• Verified date: January 2013
• Source: Johannes Gutenberg University Mainz
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical DevicesAustria: Agency for Health and Food SafetySwitzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

In this clinical trial patients with newly diagnosed focal epilepsy aged 60 years or older receive three different antiepileptic drugs in a double-blind, randomized design over a period of 58 weeks. All drugs are licensed for the treatment of epilepsy. The primary endpoint of this study will be retention rate at 58-weeks, since it reflects both efficacy and tolerability.

Description:

Indication: Focal Epilepsy Objectives: To evaluate the tolerability and efficacy of levetiracetam (LEV) in newly diagnosed elderly patients (aged 60 yrs or above) with focal epilepsy compared to lamotrigine (LTG) or carbamazepine slow release (CBZ).

Primary Outcome: The primary outcome will be the 58-week retention rate measured by the number of drop outs due to adverse events or seizures from day 1 of treatment.

Secondary Outcome: Proportion of patients remaining seizure-free at week 30 (Visit 4); proportion of patients remaining seizure free at week 58 (Visit 6); the time (in days) to first break-through seizure (from day 1 of treatment); the absolute seizure frequency during the maintenance (over 52 weeks) phase; proportion of seizure-free days during the maintenance phase for subjects who enter the maintenance phase; the frequency of adverse events (from day 1 of treatment); QOLIE-31 results at V6; Portland Neurotoxicity scale at V6; results of cognitive testing (EpiTrack© by UCB).

Trial Design: This is a randomized, double-blind, multicenter Phase IV study using a parallel group design with three treatment groups. The study will consist of a 6-week titration-phase and a 52-week maintenance phase. Patients who successfully complete the trial (final visit, V6) will be unblinded and offered either to continue on their current drug or be changed to an alternative antiepileptic drug (AED) treatment of choice.

Population: Patients aged 60 years or above with new onset focal epilepsy i.e. either at least one epileptic seizure in the last 6 months and focal epileptiform discharges on EEG or a relevant lesion on CT/MRI or a total of 2 epileptic seizures, one of which occurring in the last 6 months prior inclusion. Patients with acute (< 2 weeks) symptomatic epileptic seizures due to acute brain abnormalities (i.e. haemorrhage or cerebral infarct), or contraindications against any of the drugs in trial will be excluded.

Sample Size: 360 patients to be included, 120 patients per treatment arm. Investigational Medicinal Product(s): Levetiracetam, lamotrigine, carbamazepine-slow release Trial Duration and Dates: Duration of treatment: 6 weeks titration phase, 52 weeks maintenance phase.

Follow up: At the end of trial subjects will be unblinded and may choose to continue on the medication or taper the trial medication and be treated with an alternative drug at the investigators discretion. The patient will receive a dosing schedule and a referral letter for his/her physician.

Duration of trial: approximately 2 years. Start of recruitment: January 2007 Projected number of centres: 75 Number of countries: 3 (Germany, Switzerland, Austria).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 361
• Est. completion date: August 2011
• Est. primary completion date: July 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Age 60 yrs or above.

• New onset focal epilepsy i.e. either at least one epileptic seizure in the last 6 months and focal epileptiform discharges on EEG or a relevant lesion on CT/MRI or at least 2 epileptic seizures, one of which occurring in the last 6 months prior inclusion.

• No previous AED treatment, except for a period not longer than 4 weeks prior to inclusion (V0).

• Ability of subject to understand verbal and written instructions, to comply with all study requirements, and to comprehend character and individual consequences of the clinical trial.

• Written informed consent before enrolment in the trial.

Exclusion Criteria:

• Acute symptomatic epileptic seizures occurring acutely within a 2 week period after the onset of an acute illness such as cerebral haemorrhage, cerebral infarct, rapid progressive malignancy or other acute brain abnormalities (i.e. encephalitis, hypoxic brain damage, trauma, metabolic derangement, following brain surgery).

• Dementia (as defined by history)

• Renal insufficiency as defined by GFR < 50 mL/min.

• Increased liver enzymes (GOT, GPT, gGT) or increased bilirubin = 2-fold the upper limit of normal (ULN).

• Pre-treatment with valproic acid within the four weeks prior inclusion (V0).

• Contraindication against or history of hypersensitivity to any of the investigational medicinal products or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal products.

• Participation in other clinical trials and observation period of competing trials within the last 2 months, respectively.

• History of drug or alcohol abuse within the last 2 years.

• Medical condition which interferes with the participation in the trial according to the opinion of the investigator.

• Patients with life expectancy < 1 year due to malignant disease

• Psychiatric morbidity requiring legal guardianship.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Epilepsies, Partial
• Epilepsy
• Focal Epilepsy

Intervention

Drug:
• Levetiracetam
LEV 250 mg capusles: week 1 and 2 0-0-1, week 3 and 4 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (500 - 3000 mg)during maintenance.
• Carbamazepine
CBZ 100 mg capusles: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (200 - 1200 mg) during maintenance depending on tolerance and efficacy.
• Lamotrigine
LTG 25 mg encapsulated: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 caps. per day (50 - 300 mg)during maintenance depending on tolerance and efficacy.

Locations

Country	Name	City	State
Germany	Department of Neurology, University of Mainz Medical Centre	Mainz

Sponsors (2)

Lead Sponsor	Collaborator
Johannes Gutenberg University Mainz	UCB Pharma GmbH

Country where clinical trial is conducted

Germany, 

References & Publications (2)

Brodie MJ, Chadwick DW, Anhut H, Otte A, Messmer SL, Maton S, Sauermann W, Murray G, Garofalo EA; Gabapentin Study Group 945-212. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia. 2002 Sep;43(9):993-1000. — View Citation

Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, Uthman BM, Spitz M, Frederick T, Towne A, Carter GS, Marks W, Felicetta J, Tomyanovich ML; VA Cooperative Study 428 Group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005 Jun 14;64(11):1868-73. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment		58 weeks	No
Secondary	Time to Drop Out	number of days between randomization and premature discontinuation of the study	58 weeks	No
Secondary	Percentage of Patients Remaining Seizure-free at Week 30 (Visit 4)	Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30.	Week 30	No
Secondary	Percentage of Patients Remaining Seizure Free at Week 58 (Visit 6)	Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58.	week 58	No
Secondary	The Time (in Days) to First Break-through Seizure (From Day 1 of Treatment)		over the whole duration of 58 weeks	No
Secondary	The Absolute Seizure Frequency During the Maintenance Phase (Weeks 7 - 58)	Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.; The absolute seizure frequency during the maintenance phase was defined as the sum of those entries.	over 52 weeks	No
Secondary	Proportion of Seizure-free Days During the Maintenance Phase for Subjects Who Enter the Maintenance Phase		52 weeks	No
Secondary	QOLIE-31 (Quality Of Life In Epilepsy) Results at V6	The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100.	58 weeks, final visit	No
Secondary	Portland Neurotoxicity Scale (PNS) at V6	The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.; Lower values indicate better quality of life.	at week 58	No
Secondary	Results of Cognitive Testing (EpiTrack© by UCB) - Score at V6	EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45.	week 58	No
Secondary	Results of Cognitive Testing (EpiTrack© by UCB) - Categories at V6	Evaluation of current testing at V6: =29 score points: Inconspicuous; 26 to 28 score points: Borderline; =25 score points: Impaired	58 weeks	No
Secondary	Results of Cognitive Testing (EpiTrack© by UCB) - Changes to Baseline (V0) at Week 58 (V6)	Evaluation of Changes; Changes in the EpiTrack® Score were categorized as follows: =5 score points: Improved; -3 to 4 score points: Unchanged; =-4 score points: Worsened	week 58	No